棕榈酸帕利哌酮与注射用利培酮微球治疗精神分裂症的疗效比较  

Comparison of Efficacy of Paliperidone Palmitate and Risperidone for Depot Suspension in the Treatment of Schizophrenia

作　　者：宋国华[1] 杨剑虹[1] 卢桂华[1] 

机构地区：[1]浙江省湖州市第三人民医院精神科,湖州313000

出　　处：《医药导报》2016年第10期1072-1075,共4页Herald of Medicine

摘　　要：目的探讨棕榈酸帕利哌酮注射液与注射用利培酮微球治疗精神分裂症的疗效及安全性。方法 80例精神分裂症患者,采用随机数字表法分为棕榈酸帕利哌酮注射液组(n=40)和注射用利培酮微球组(n=40),均为肌内注射,治疗12周。棕榈酸帕利哌酮注射液组平均治疗剂量为(97.44±21.30)mg,注射用利培酮微球组平均治疗剂量为(29.69±8.34)mg。采用阳性与阴性症状量表(PANSS)及治疗时出现症状量表(TESS)分别评定临床疗效及不良反应。结果治疗2周末开始两组PANSS评分较治疗前显著降低(P<0.05);两组间各时点PANSS评分比较差异无统计学意义(P>0.05);至12周末,棕榈酸帕利哌酮注射液组总有效率为82.1%,注射用利培酮微球组总有效率为80.0%,两组比较差异无统计学意义(P>0.05)。两组不良反应主要为失眠、锥体外系反应、月经紊乱、体质量增加、注射部位疼痛等,但棕榈酸帕利哌酮注射液组体质量增加发生率明显少于注射用利培酮微球组(P<0.05),两组其他不良反应差异无统计学意义(P>0.05)。两组均无严重不良反应。结论棕榈酸帕利哌酮注射液与注射用利培酮微球治疗精神分裂症疗效相当,均可有效改善精神分裂症临床症状,不良反应较少,安全性好。Objective To investigate the efficacy and safety of paliperidone palmitate injection and risperidone for depot suspension in treatment of patients with schizophrenia. Methods Eighty patients with schizophrenia were randomly divided into paliperidone palmitate injection group（n=40） and risperidone for depot suspension group（n=40）.Both groups were treated with intramuscular injection once daily for 12 weeks.The average dose of paliperidone palmitate injection was （97.44±21.30） mg,and that of risperidone for depot suspension was （29.69±8.34） mg.Clinical efficacy was assessed with the positive and negative syndrome scale （PANSS）,and adverse reactions with the treatment of symptoms scale （TESS）. Results The scores of PANSS in the two groups at the 2th weekend of treatment were decreased significantly as compared to those before treatment （P〈0.05）;The scores of PANSS in the two groups had no significant difference at different points in time after treatment （P〉0.05）.At the end of 12th week,the total effective rate in the paliperidone palmitate injection group was 82.1%,and that of risperidone for depot suspension group was 80.0%, there was no significant difference （P〉0.05）.Main adverse reactions of both groups were insomnia,extrapyramidal reactions,menstrual disorders,weight gain,injection site pain,and so on.The weight gain of the paliperidone palmitate injection group was significantly less than that of the risperidone for depot suspension group （P〈0.05）.The other adverse reactions were not statistically different between the two groups （P〉0.05）.There were no serious adverse reactions in both groups. Conclusion Paliperidone palmitate injection and risperidone for depot suspension have equivalent efficacy in the treatment of schizophrenia.Both of them can effective lyimprove psychiatric symptoms of schizophrenia with less adverse reactions and high safety.

关 键 词：帕利哌酮 棕榈酸 利培酮微球 注射用 精神分裂症 

分 类 号：R971.41[医药卫生—药品] R749.3[医药卫生—药学]